interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Famotidine

Generic competition · all medicines · read 12 November 2026

Is there a generic of Famotidine, and who makes it?

Famotidine appears in 6 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 38 generic makers listed as marketed across them. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came between 4.9 and 23.3 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Famotidine6 dosage-form groups in the Orange Book
38generic makers listed
  1. Famotidine appears in 6 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 38 generic makers listed as marketed across them.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came between 4.9 and 23.3 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Four or more generic makers listed

Brand listed as marketed: Pepcid Ac. 22 generic makers with 55 generic products listed as marketed; the first generic approval is dated 16 April 2001.

1985199019952000200520102015202020252030022brand 1986Carlsbad Technology Inc, first approval 16 April 2001Chartwell Rx Sciences Llc, first approval 16 April 2001Dr Reddys Laboratories Ltd, first approval 16 April 2001Ivax Pharmaceuticals Inc Sub Teva Pharmaceuticals Usa, first approval 16 April 2001Mankind Pharma Ltd, first approval 16 April 2001Rising Pharma Holding Inc, first approval 16 April 2001P And L Development Llc, first approval 26 July 2001Glenmark Pharmaceuticals Inc Usa, first approval 7 March 2005L Perrigo Co, first approval 18 March 2005Perrigo R And D Co, first approval 25 September 2006Alembic Pharmaceuticals Ltd, first approval 22 May 2009Aurobindo Pharma Ltd, first approval 22 December 2015Ascent Pharmaceuticals Inc, first approval 15 October 2021Annora Pharma Private Ltd, first approval 4 November 2021Vkt Pharma Private Ltd, first approval 7 January 2022Zydus Pharmaceuticals Usa Inc, first approval 3 June 2022Pharmazone, first approval 8 March 2023Alkem Laboratories Ltd, first approval 24 April 2023Contract Pharmacal Corp, first approval 20 December 2023Graviti Pharmaceuticals Private Ltd, first approval 14 March 2024Msn Laboratories Private Ltd, first approval 6 August 2024Regcon Holdings Llc, first approval 25 March 2025data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Carlsbad Technology Inc16 April 20012
Chartwell Rx Sciences Llc16 April 20012
Dr Reddys Laboratories Ltd16 April 20014
Ivax Pharmaceuticals Inc Sub Teva Pharmaceuticals Usa16 April 20012
Mankind Pharma Ltd16 April 20012
Rising Pharma Holding Inc16 April 20014
P And L Development Llc26 July 20011
Glenmark Pharmaceuticals Inc Usa7 March 20052
L Perrigo Co18 March 20051
Perrigo R And D Co25 September 20061
Alembic Pharmaceuticals Ltd22 May 20092
Aurobindo Pharma Ltd22 December 20154

10 more makers are listed in the data.

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Injectable, Injection

Four or more generic makers listed

Every brand product here is listed as discontinued. 6 generic makers with 12 generic products listed as marketed; the first generic approval is dated 16 April 2001.

198519901995200020052010201520202025203006brand 1986Fresenius Kabi Usa Llc, first approval 16 April 2001Hikma Pharmaceuticals Usa Inc, first approval 16 April 2001Sagent Pharmaceuticals, first approval 16 April 2001Baxter Healthcare Corp, first approval 10 May 2001Mylan Laboratories Ltd, first approval 25 June 2008Lupin Ltd, first approval 12 May 2026data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Fresenius Kabi Usa Llc16 April 20012
Hikma Pharmaceuticals Usa Inc16 April 20012
Sagent Pharmaceuticals16 April 20014
Baxter Healthcare Corp10 May 20011
Mylan Laboratories Ltd25 June 20082
Lupin Ltd12 May 20261

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

For Suspension, Oral

Four or more generic makers listed

Every brand product here is listed as discontinued. 17 generic makers with 18 generic products listed as marketed; the first generic approval is dated 27 May 2010.

1985199019952000200520102015202020252030017brand 1987Navinta Llc, first approval 27 May 2010Lupin Ltd, first approval 29 June 2010Novel Laboratories Inc, first approval 17 December 2012Novitium Pharma Llc, first approval 30 May 2014Amneal Pharmaceuticals Llc, first approval 4 August 2022Alkem Laboratories Ltd, first approval 15 May 2023Somerset Therapeutics Llc, first approval 16 June 2023Carnegie Pharmaceuticals Llc, first approval 7 July 2023Annora Pharma Private Ltd, first approval 17 August 2023Micro Labs Ltd, first approval 14 September 2023Ajanta Pharma Ltd, first approval 18 September 2023Pharmazone, first approval 16 January 2024Epic Pharma Llc, first approval 16 October 2024Lannett Co Inc, first approval 2 June 2025Aurobindo Pharma Ltd, first approval 9 July 2025Msn Laboratories Private Ltd, first approval 24 July 2025Contract Pharmacal Corp, first approval 9 March 2026data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Navinta Llc27 May 20101
Lupin Ltd29 June 20101
Novel Laboratories Inc17 December 20121
Novitium Pharma Llc30 May 20142
Amneal Pharmaceuticals Llc4 August 20221
Alkem Laboratories Ltd15 May 20231
Somerset Therapeutics Llc16 June 20231
Carnegie Pharmaceuticals Llc7 July 20231
Annora Pharma Private Ltd17 August 20231
Micro Labs Ltd14 September 20231
Ajanta Pharma Ltd18 September 20231
Pharmazone16 January 20241

5 more makers are listed in the data.

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Tablet, Orally Disintegrating, Oral

Nothing listed as marketed

Every brand product here is listed as discontinued. No generic is listed as marketed.

1995200020052010201520202025203001brand 1998data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Solution, Intravenous

Nothing listed as marketed

Every brand product here is listed as discontinued. No generic is listed as marketed.

20202025203001brand 2025data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Tablet, Chewable, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Pepcid Ac. No generic is listed as marketed (1 generic product listed as discontinued).

1995200020052010201520202025203001brand 1998data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.